After 12 weeks, we found that TAM recruitment to the cancer site was significantly increased in mice injected with HER2-overexpressed cancer cells compared to that in mice injected with Vec cells through CD163 staining (Figure 6B). This evidence concerns the gene ERBB2 and cancer.